We recently published a list of 12 Safe Stocks to Buy for the Long Term in 2025. In this article, we are going to take a look ...

While companies like DeepSeek may find success in certain market segments, they face an uphill battle against this massive ...

Drugmakers raised the list prices of more than 800 prescription drugs for blood pressure, cancer and other conditions by a ...

Financial analysis of Pfizer Inc. stock ahead of its earnings release. PFE faces significant headwinds from patent expiries, click for my updated look at the stock.

Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by ...

Pfizer PFE will report its fourth-quarter and full-year 2024 earnings on Feb. 4, before market open. The Zacks Consensus ...

Starboard last year took a $1 billion stake in Pfizer, looking to turn the pharma around after alleged severe shortcomings by ...

Citi analyst Geoff Meacham lowered the firm’s price target on Pfizer (PFE) to $29 from $30 and keeps a Neutral rating on the shares. Ahead of ...

When paired with dividend reinvestment, high-yield dividend stocks have demonstrated remarkable outperformance compared to ...

Wen Shuhao helped speed up the development of Pfizer’s Covid oral drug, Paxlovid. Now the chairman of Xtalpi wants to help ...

A new study led by researchers at Moffitt Cancer Center shows that asymptomatic brain metastasis is more common in stage 4 breast cancer patients than previously believed. The study, published in ...

Following a tough opening salvo from Starboard Value last fall, Pfizer is getting a chance to catch its breath in the ...